CD276 and cancer: Strong justification exists for using B7-H3-specific inhibitory monoclonal antibodies (mAbs) in the management of solid tumors due to the substantial alterations in cancer cells brought about by silencing of B7-H3 and the remarkable therapeutic outcomes of mAbs that block checkpoint molecules.